Drug Penetrance of Veliparib and Carboplatin in TNBC Drug Penetrance of Veliparib and Carboplatin in TNBC
Researchers investigate whether non-response to chemotherapy in TNBC is due to insufficient drug penetration.Breast Cancer Research
Publication date: November 2018Source: Academic Radiology, Volume 25, Issue 11Author(s): Rossella Rella, Paolo Belli, Michela Giuliani, Enida Bufi, Giorgio Carlino, Pierluigi Rinaldi, Riccardo ManfrediAutomated breast ultrasonography (ABUS) is a new imaging technology for automatic breast scanning through ultrasound. It was first developed to overcome the limitation of operator dependency and lack of standardization and reproducibility of handheld ultrasound. ABUS provides a three-dimensional representation of breast tissue and allows images reformatting in three planes, and the generated coronal plane has been suggested t...
In conclusion, the results of the present study revealed that HDAC inhibitors increase the sensitivity to 5-FU in 5-FU-sensitive and -resistant cells. PMID: 30333885 [PubMed]
The trial, at hundreds of sites in 41 countries, followed 902 patients and studied the combination of immunotherapy and chemotherapy
This study explores the breast tumor regression in vivo by synergistic photothermal-chemotherapy based on liposomal nanocomplex (folic acid-gold nanorods-anticancer drug-liposome). The proposed liposomal nanocomplex can enhance the tumor targeting by functionalizing folic acid (FA) molecules on the surface of liposome that encapsulates both gold nanorods (AuNRs) and the doxorubicin (DOX) to combine the photothermal therapy and the chemotherapy, respectively. Herein, 7-nm gold nanorods were fabricated and co-encapsulated with DOX into nanoliposomes functionalized with FA, with an average diameter of 154 nm, for activ...
A newer immunotherapy drug for the first time has shown promise against breast cancer in a large study that combined it with chemotherapy to treat an aggressive form of the disease
A combination of chemotherapy and immunotherapy added months to the lives of women with triple-negative breast cancer, an aggressive type that attacks women under 50.
For the first time, a survival benefit with immunotherapy has been shown in breast cancer with atezolizumab plus chemotherapy in triple negative patients.Medscape Medical News
Combining immunotherapy and chemotherapy can help women with an aggressive type of breast cancer and should become their new standard of care.
This study is proof of principle that we should keep going,” Litton says. She is investigating whether there is a way for people who have already started chemotherapy to learn whether they will respond to the standard cycle of chemotherapy drugs, or should be switched to immunotherapy combinations for better results. Adams is also hopeful that other immunotherapy drugs may be developed that are more effective in activating the immune system against breast cancer cells specifically. “I expect these results will really invigorate the field and bring new research to help patients,” she says.
Roche today announced positive results from the Phase III IMpassion130 study of Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).